CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
抗体可变区工程改造以改善肿瘤免疫治疗
英文原题：Antibody variable region engineering for improving cancer immunotherapy.
查看英文原题
Antibody variable region engineering for improving cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
传统单克隆抗体（mAb）药物在临床中的疗效和特异性仍有待进一步提高。目前，开发和应用新型抗体形式以改善癌症免疫治疗备受关注。保留可变区的抗体片段，如抗原结合片段（Fab）、单链可变片段（scFv）、双特异性抗体以及双/三特异性细胞衔接器，可通过人源化、多价抗体构建、亲和力优化及抗体屏蔽等工程化手段，靶向肿瘤细胞和杀伤细胞，从而提高抗体治疗的效力、疗效和特异性。本综述总结抗体可变区工程化的应用，并探讨通过抗体工程改进癌症治疗的未来方向。
展开英文摘要原文
The efficacy and specificity of conventional monoclonal antibody (mAb) drugs in the clinic require further improvement. Currently, the development and application of novel antibody formats for improving cancer immunotherapy have attracted much attention.
Variable region-retaining antibody fragments, such as antigen-binding fragment (Fab), single-chain variable fragment (scFv), bispecific antibody, and bi/trispecific cell engagers, are engineered with humanization, multivalent antibody construction, affinity optimization and antibody masking for targeting tumor cells and killer cells to improve antibody-based therapy potency, efficacy and specificity.
In this review, we summarize the application of antibody variable region engineering and discuss the future direction of antibody engineering for improving cancer therapies.
论文信息
- 作者
- Lou H、Cao X
- 第一作者单位
- Ludwig Institute of Cancer Research, University of Oxford, Oxford, OX3 7DR, UK.United Kingdom
- 通讯作者单位
- Chinese Academy for Medical Sciences Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ, UK.United Kingdom
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cancer communications (London, England)2022 Sep
- 原文标识
- PubMed 35822503 · DOI 10.1002/cac2.12330
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →